866-997-4948(US-Canada Toll Free)

Global Non-alcoholic Steatohepatitis Market 2016-2020

Published By :

Technavio

Published Date : May 2016

Category :

Metabolic Disorders

No. of Pages : 70 Pages

About Non-Alcoholic Steatohepatitis (NASH)

NAFL disease, also known as fatty infiltration, is characterized by the accumulation of fat in the liver. It is of two types: NAFL and NASH. Fatty inflammation characterized by higher fat deposition than the normal level, 5%-10%, causes the disease. NASH causes severe inflammation of the liver, leading to damage of the organ. It is a benign condition of unknown etiology and is asymptomatic in nature during its initial stages, resulting in late diagnosis. Conditions such as obesity, diabetes, hyperlipidemia, insulin resistance, and toxicity by drugs such as amiodarone, tamoxifen, and perhexiline maleate can cause NASH.

Technavios analysts forecast the global NASH market to grow at a CAGR of 24.58% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global NASH market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of off-label drugs, originally indicated for the treatment of diabetes, obesity, and associated conditions.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global NASH Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Arena Pharmaceuticals
AstraZeneca
F Hoffmann-La Roche
GSK
Novo Nordisk
Vivus

Other prominent vendors
Arisaph Pharmaceuticals
Cempra Pharmaceuticals
Galectin Therapeutics
Galmed Pharmaceuticals
Genfit
Gilead
Immuron
Interceptpharma
Raptor Pharmaceutical
Shire
Tobira Therapeutics
Verva
Viking Therapeutics

Market driver
Increase in sedentary lifestyle
For a full, detailed list, view our report

Market challenge
Limited understanding of disease pathophysiology
For a full, detailed list, view our report

Market trend
Patient assistance programs
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding the disease
Symptoms and signs
Pathophysiology
Risk factors
Diagnosis
Treatment
Epidemiology
Economic burden
PART 06: Pipeline analysis
Pipeline information of NASH
Clinical trials for NASH
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Market segmentation by dosage form
Solid
Liquid
PART 09: Market segmentation by route of administration
Oral
Parenteral
PART 10: Geographical segmentation
Global NASH drugs market by geographical segmentation 2015-2020
NASH drugs market in Americas
NASH drugs market in US
NASH drugs market in EMEA
NASH drugs market in APAC
PART 11: Market drivers
Increase in sedentary lifestyle
Prevalence of associated health conditions
Promising pipeline
Significant unmet medical needs
PART 12: Impact of drivers
PART 13: Market challenges
Limited understanding of disease pathophysiology
Insufficient diagnostic technology for NASH
Stringent regulatory procedure
Adverse effects of drugs
PART 14: Impact of drivers and challenges
PART 15: Market trends
Rise in public awareness
Increase in strategic alliances
Patient assistance programs
Usage of off-label drugs
PART 16: Vendor landscape
Competitive scenario
Arena Pharmaceuticals
AstraZeneca
F Hoffmann-La Roche
GSK
Novo Nordisk
Vivus
Other prominent vendors
PART 17: Appendix
List of abbreviations
PART 18: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Conditions associated with NASH
Exhibit 03: Diagnosis of NASH
Exhibit 04: Global NASH drugs market: Pipeline portfolio
Exhibit 05: Clinical trials for NASH by development phase
Exhibit 06: Clinical trials for NASH by trial status
Exhibit 07: Global NASH drugs market 2015-2020 ($ millions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global NASH drugs market by dosage form
Exhibit 10: Segmentation of global NASH drugs market by route of administration
Exhibit 11: Global NASH drugs market by geographical segmentation 2015
Exhibit 12: Global NASH drugs market revenue by geography 2015-2020 ($ millions)
Exhibit 13: NASH drugs market in Americas 2015-2020 ($ millions)
Exhibit 14: NASH market in US 2015-2020 ($ millions)
Exhibit 15: NASH drugs market in EMEA 2015-2020 ($ millions)
Exhibit 16: NASH drugs market in APAC 2015-2020 ($ millions)
Exhibit 17: Impact of drivers
Exhibit 18: Impact of drivers and challenges
Exhibit 19: Arena Pharmaceuticals: YoY revenue of Belviq 2013-2014 ($ millions)
Exhibit 20: Arena Pharmaceuticals: Key takeaways
Exhibit 21: AstraZeneca: Cardiovascular and metabolic diseases segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 22: Top selling products in 2014 ($ millions)
Exhibit 23: AstraZeneca: YoY growth and revenue of Bydureon 2012-2014 ($ millions)
Exhibit 24: AstraZeneca: YoY growth and revenue of Byetta 2012-2014 ($ millions)
Exhibit 25: AstraZeneca: YoY growth and revenue of Onglyza/ Komboglyze/ Komboglyze XR 2012-2014 ($ millions)
Exhibit 26: AstraZeneca: Key takeaways
Exhibit 27: Roche: Key takeaways
Exhibit 28: GSK: Key takeaways
Exhibit 29: Novo Nordisk: Business segmentation by revenue 2014
Exhibit 30: Novo Nordisk: R&D expenditure 2014
Exhibit 31: Novo Nordisk: YoY growth and revenue of NovoLog/NovoRapid 2012-2014 ($ millions)
Exhibit 32: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog mix 2012-2014 ($ millions)
Exhibit 33: Novo Nordisk: YoY growth and revenue of Prandin 2012-2014 ($ millions)
Exhibit 34: Novo Nordisk: Key takeaways
Exhibit 35: Vivus: YoY growth and revenue of Qsymia 2012-2014 ($ millions)
Exhibit 36: Vivus: Key takeaways

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *